Conventional cell analysis methods depend on fluorescent labels, manual workflows, and endpoint assays that create blind spots in some of the most critical phases of advanced therapy development. For researchers and biomanufacturers operating under tight timelines and increasingly stringent regulatory expectations, those blind spots translate directly into delayed decisions, inconsistent product quality, and increased risk.
LumaCyte’s Radiance® platform, powered by proprietary Laser Force Cytology™ (LFC) technology, addresses this gap with real-time, label-free single cell analysis built for the complexity of modern bioprocessing. Radiance® delivers unbiased, high-resolution cellular data across a broad range of applications, from viral vector infectivity quantification and cell vitality profiling to predictive stem cell and CAR-T potency characterization, PAT-compliant biomanufacturing analytics, and vaccine lot release. The result is a faster, more confident path from research through clinical production for the therapies that matter most.
Explore how Radiance® is applied across each application area below.

